Monitoring detected blood cancers with less marrow scarring
The median share of JAK2 gene copies carrying a mutation was 13.0% at diagnosis in monitored cases versus 41.3% in referral-diagnosed cases.
Our read
Interventions- Studied:
- Cohort study of 61 JAK2 mutation carriers, against referral-diagnosed blood cancer cases
- What changed:
- No marrow scarring was found in 80% of surveillance-detected cases versus 15% of referral-diagnosed cases
- The catch:
- Referral-diagnosed cases may have had faster-progressing disease than surveillance-detected cases
- In the record:
- The 3rd paper on active surveillance with results in people; 17 on record in all.
Editor of record: Boris Djordjevic · AgingResearch.News
Sixty-one participants in Denmark carrying a mutation in the JAK2 gene underwent active surveillance for myeloproliferative neoplasms, a group of blood cancers, in a longitudinal observational study. They had none of these cancers at baseline in 2010–2013. Researchers compared 20 cancers diagnosed during surveillance with 20 diagnosed after clinical referral between 2010 and 2018. Median follow-up to cancer diagnosis was 7.4 years.
Surveillance-detected cancers had a lower share of gene copies carrying the mutation and less bone marrow fibrosis, or scarring. No marrow scarring was found in 80% of surveillance-detected cases versus 15% of referral-diagnosed cases. The other 41 monitored participants did not develop these cancers or show an increase in the mutation’s share of gene copies.
Why it matters
For aging research on mutation-carrying blood cell populations, the study addresses whether surveillance can identify related blood cancers earlier in their development.
Caveats
The comparison involved cancers detected through different routes. People diagnosed after clinical referral may have had faster-progressing disease than those diagnosed through surveillance.
Where the evidence stands
Active surveillance
- 2 independent labs in 2 countries
- Active surveillance
- Myeloproliferative neoplasm
- Bone marrow fibrosis
- Clonal hematopoiesis of indeterminate potential
- JAK2V617F variant allele frequency
- Humans
The paper
Active Surveillance of JAK2V617F Clonal Hematopoiesis Toward Myeloproliferative Neoplasms
Zealand University Hospital; University of Copenhagen
Blood Advances, Nov 10, 2026, CC BY-NC-ND
Comments
Be the first to comment.